Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
<p><strong>Objective:</strong> To determine whether early changes in disease activity predict later achievement of low disease activity (LDA) or remission in patients treated with baricitinib 4 mg in global phase 3 studies.</p> <p><strong>Methods:</strong>...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | Japanese |
| Published: |
Iyaku-Joho-Kenkyujo, Inc.
2021
|